Last reviewed · How we verify

IR CD-LD — Competitive Intelligence Brief

IR CD-LD (IR CD-LD) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine replacement therapy / Decarboxylase inhibitor combination. Area: Neurology.

phase 3 Dopamine replacement therapy / Decarboxylase inhibitor combination Dopamine pathway; carbidopa inhibits aromatic L-amino acid decarboxylase Neurology Small molecule Live · refreshed every 30 min

Target snapshot

IR CD-LD (IR CD-LD) — Impax Laboratories, LLC. IR CD-LD is an immediate-release combination of carbidopa and levodopa designed to improve dopamine replacement therapy in Parkinson's disease with potentially faster onset and more consistent symptom control.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IR CD-LD TARGET IR CD-LD Impax Laboratories, LLC phase 3 Dopamine replacement therapy / Decarboxylase inhibitor combination Dopamine pathway; carbidopa inhibits aromatic L-amino acid decarboxylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine replacement therapy / Decarboxylase inhibitor combination class)

  1. Impax Laboratories, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IR CD-LD — Competitive Intelligence Brief. https://druglandscape.com/ci/ir-cd-ld. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: